Population‐wide long‐term study of incidence, renal failure, and mortality rates for lupus nephritis
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15079 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Johannes C Nossent und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Lupus Nephritis, Kidney Failure, Chronic, Glomerulonephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Arthritis Foundation of Western Australia.
Abstract (Originalsprache)
Objective
Given limited regional data, we investigate the state‐wide epidemiology, renal and patient outcomes for lupus nephritis (LN) in Western Australia (WA).
Methods
Patients hospitalized with incident SLE (≥2 diagnostic codes in the state‐wide WA Health Hospital Morbidity Data Collection) in the period 1985–2015 were included ( n = 1480). LN was defined by the presence of glomerulonephritis and/or raised serum creatinine. Trends over three study decades for annual incidence rate (AIR)/100.000 population, mortality (MR), and end‐stage renal disease (ESRD) rates/100 person years were analyzed by least square regression and compared with a matched control group ( n = 12 840).
Results
Clinical evidence of LN developed in 366 SLE patients (25.9%) after a median disease duration of 10 months (IQR 0–101) with renal biopsy performed in 308 (84.2%). The AIR for LN (0.63/100.000) did not change significantly over time ( R 2 = .11, p = .85), while point prevalence reached 11.9/100.000 in 2015. ESRD developed in 14.1% ( n = 54) of LN patients vs. 0.2% in non‐LN SLE patients and 0.05% in controls (all p ≤ 0.01). ESRD rates increased over time in LN patients (0.4 to 0.7, R 2 = .52, p = .26). The odds ratio for death was 8.81 (CI 3.78–22.9) for LN and 6.62 (CI 2.76–17.9) for non‐LN SLE patients compared to controls and MR for LN patients increased over time (1.3 to 2.2, R 2 = .84, p = .26).
Conclusions
The incidence rate of LN in WA remained unchanged over 30 years. A lack of improvement in renal failure and mortality rates illustrates the pressing need for better long‐term treatment options and/or strategies in LN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
- Rheumatology Group, School of Medicine, University Western Australia, Crawley, Western Australia, Australia.
- Department of Rheumatology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
- School of Population and Global Health, University Western Australia, Crawley, Western Australia, Australia.
ORCID-Profile: Johannes C Nossent, Helen I Keen, David B Preen, Charles A Inderjeeth
Förderung
- The Arthritis Foundation of Western Australia
Zitieren
APA
Nossent, J. C., Keen, H. I., Preen, D. B., & Inderjeeth, C. A. (2024). Population‐wide long‐term study of incidence, renal failure, and mortality rates for lupus nephritis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15079
Vancouver
Nossent JC, Keen HI, Preen DB, Inderjeeth CA. Population‐wide long‐term study of incidence, renal failure, and mortality rates for lupus nephritis. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15079
BibTeX
@article{Nossent2024,
author = {Nossent, Johannes C and Keen, Helen I and Preen, David B and Inderjeeth, Charles A},
title = {Population‐wide long‐term study of incidence, renal failure, and mortality rates for lupus nephritis},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15079}
}
EUVIMED